Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab + lenalidomide versus rituximab + lenalidomide in relapsed or refractory follicular lymphoma
2023-505807-21-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab, lenalidomide and rituximab in follicular lymphoma (FL) (3 arms), sponsored by Roche. Primary endpoints: Progression-free survival and Objective response rate. Planned start Nov 2021; status: authorised.
02
Drugs
mosunetuzumablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-505807-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505807-21-00.